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The overall prognosis for operable gastro-oesophageal adenocarcinoma remains poor and therefore
neoadjuvant chemotherapy has become the standard of care, in addition to radical surgery. Certain
anticancer agents (e.g. anthracyclines and cisplatin) generate damaging reactive oxygen species as by-
products of their mechanism of action. Drug effectiveness can therefore depend upon the presence of
cellular redox buffering systems that are often deregulated in cancer. The expression of the redox protein,
thioredoxin interacting protein, was assessed in gastro-oesophageal adenocarcinomas. Thioredoxin
interacting protein expression was assessed using conventional immunohistochemistry on a tissue
microarray of 140 adenocarcinoma patients treated by primary surgery alone and 88 operable cases
treated with neoadjuvant chemotherapy. In the primary surgery cases, high thioredoxin interacting
protein expression associated with a lack of lymph node involvement (p¼0.005), no perineural invasion
(p¼0.030) and well/moderate tumour differentiation (p¼0.033). In the neoadjuvant tumours, high
thioredoxin interacting protein expression was an independent marker for improved disease speciﬁc
survival (p¼0.002) especially in cases with anthracycline-based regimes (p¼0.008). This study high-
lights the potential of thioredoxin interacting protein as a biomarker for response in neoadjuvant treated
gastro-oesophageal adenocarcinoma and may represent a useful therapeutic target due to its association
with tumour progression.
& 2013 The Authors. Published by Elsevier B.V. Open access under CC BY-NC-ND license.Introduction
The overall prognosis for patients with gastro-oesphageal adeno-
carcinomas remains poor and although radical surgery plays a critical
role in the management of operable disease, additional therapy is
required to improve patient outcomes. The United Kingdom Medical
Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC)
trial demonstrated a 25% reduction in the risk of death and a
signiﬁcant improvement in 5 year survival in patients given neoad-
juvant chemotherapy compared to those treated with surgery alone
[1]. Similar survival beneﬁts have also been demonstrated in the MRCB.V.
School of Molecular Medical
University Hospitals NHS
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Open access under CC BY-NC-NDOEO2 trial of surgical resection with or without neoadjuvant che-
motherapy (consisting of two cycles of cisplatin and 5-FU chemother-
apy) in oesophageal cancer [2]. A recent meta-analysis from 14 trials
has also provided further evidence in favour of neoadjuvant che-
motherapy on survival in gastric cancer patients [3]. However,
delaying surgery in patients that do not respond to neoadjuvant
therapy may have a negative inﬂuence on clinical outcome. In
addition the role of adjuvant chemotherapy in patients who do not
respond to neoadjuvant chemotherapy is unknown.
The generation of free radicals has been associated with the
cytotoxicity of conventional chemotherapy agents commonly
used in the treatment of gastro-oesophageal cancers i.e. cisplatin
and more recently epirubicin. Platinum has been a major advance in
improving patient outcome with a response rate in gastro-
oesophageal tumours of about 40% [1,4]. Although recognised as
causing DNA crosslinking, platinum agents also generate free radicals
when mixed in a cell-free system with DNA [5] and interaction with
radical scavengers and antioxidants such as thioredoxin, decrease
their cytotoxic effects [6,7]. Anthracycline based drugs also generate
reactive oxygen species (ROS) when their quinone undergoes license.
Table 1
Clinical characteristics of patients.
Neoadjuvant
chemotherapy
Surgery
N (%) N (%)
Total number of patients 88 140
Median Age (years) 63 74
Sex
Male 73 (83) 104 (74)
Female 15 (17) 36 (26)
Site of tumour
Gastric 20 (23) 127 (91)
GOJ 41 (46) 13 (9)
Lower third of oesophagus 27 (31) –
Surgery
Total gastrectomy 22 (25) 69 (49)
Partial gastrectomy 5 (6) 52 (37)
Oesophagectomy/
oesophagogastrectomy
61 (69) 19 (14)
Disease Speciﬁc Survival
Alive 30 (34) 42 (30)
Died due to cancer 48 (55) 52 (37)
Other 10 (11) 46 (33)
Recurrence
None 39 (44) 86 (61)
Recurrence 49 (56) 53 (38)
Unknown – 1 (1)
C.M. Woolston et al. / Redox Biology 1 (2013) 285–291286reduction to a semiquinone free radical, in the presence of oxygen.
After dismutation, resultant hydrogen peroxide can be converted into
the highly damaging hydroxyl radical. The semiquinone radical can
also intercalate and damage DNA [8,9].
Multiple mechanisms maintain the redox state of cells and can
protect them from oxidative stress. In cancer, these systems are often
deregulated/overexpressed to compensate for the increased oxidative
stress caused by the accelerated proliferation, altered metabolic
activity and persistent growth promoting signalling of tumours
[10,11]. One of the key systems involved is the thioredoxin system,
exerting its main function as an antioxidant via thioredoxins inter-
action with its downstream peroxiredoxins [12,13]. Thioredoxin
interacting protein (TxNIP), also known as vitamin D3 upregulated
protein-1 (VDUP-1), is best known as a competitive inhibitor for
thioredoxin and is down regulated in a number of cancers [14,15]. It
has been previously demonstrated, via RT-PCR, that Thioredoxin
interacting protein gene expression is signiﬁcantly lower in colorectal
and gastric cancers than in adjacent normal tissues [16].
Thioredoxin interacting proteins importance in anthracycline
based chemotherapy response has recently been demonstrated,
via immunohistochemistry, in locally advanced primary breast
cancer [17]. It was found to be an independent prognostic factor
for distant metastasis free survival and overall survival. Therefore,
the current study was conducted to examine the prognostic and
predictive value of Thioredoxin interacting protein expression in
gastro-oesophageal adenocarcinoma patients treated with reactive
oxygen species generating chemotherapy agents, including a
signiﬁcant proportion with anthracycline based regimes, and as a
comparison, in cases with primary surgery alone.Table 2
Pathological criteria of patients showing association with Thioredoxin interacting
protein expression n¼po0.05 nn¼po0.01.
Neoadjuvant Chemotherapy (N¼88) Surgery (N¼140)
N (%) p Value N (%) p Value
T stage
T0,1,2 26 (30) 0.365 62 (44) 0.113
T3,4 61 (69) 78 (56)
Tx 1 (1) –
N stage
N0 22 (25) 0.046n 33 (24) 0.005nn
≥N1 66 (75) 107 (76)
M stage
M0/Mx 83 (94) N/A 138 (99) N/A
M1 5 (6) 2 (1)
Overall stage
1,2 26 (30) 0.484 61 (44) 0.162
3,4 62 (70) 79 (56)
Tumour regression grade response after chemotherapy
1,2,3 39 (44) 0.300 34 (24) 0.970
4,5 49 (56) 105 (75)
Unknown – 1 (1)
Vascular invasion
No 40 (46) 0.404 44 (31) 0.338
Yes 48 (54) 96 (69)
Perineural invasion
No 75 (85) 0.469 75 (54) 0.030n
Yes 13 (15) 65 (46)
Differentiation of tumour
well/moderate 42 (48) 0.738 62 (44) 0.033n
poor 46 (52) 78 (56)Materials and methods
Clinical samples
The study is reported according to REMARK criteria [18]. Tissue
was obtained from patients treated at Nottingham University Hospi-
tals Trust between 2001 and 2008. The cohort consisted of two sets
of patients, 140 adenocarcinoma primary surgery cases that had not
been exposed to neoadjuvant treatment and 88 operable adenocar-
cinoma cases that had at least one cycle of neoadjuvant chemother-
apy [19]. During the study period, patients in the neoadjuvant arm
were treated with either neoadjuvant ECF [Epirubicin (50 mg/m2),
Cisplatin (60 mg/m2) and continuous infusional 5-FU (200 mg/m2
per day)] or ECX [Epirubicin (50 mg/m2), Cisplatin (60 mg/m2) and
capecetabine (625 mg/m2 p.o. b.d continuously)] chemotherapy, up
to three cycles prior to surgery, or CF [cisplatin (80 mg/m2) and
infusional 5-FU (1000 mg/m2 daily for 4 days)] chemotherapy up to
two cycles prior to surgery. The remaining three patients had either
Carbo/F or CX. The tumours analysed in the neoadjuvant arm were
from surgical samples post neoadjuvant treatment.
Median follow up was 28.4 and 27.3 months and median time to
recurrence was 9.1 and 10.2 months for the neoadjuvant and
primary surgery cohorts respectively. Disease speciﬁc survival was
calculated from the date of diagnosis until 26th November 2010
when any remaining survivors were censored. Tumour regression
grade (TRG) was deﬁned as per Mandard's criteria [20]. Tables 1 and
2 show the full clinicopathological characteristics of the patient
cohort. The conduct of this study was approved by the Ethics
Committee of Nottingham University Hospitals.
Tissue microarray
TMAs were constructed as described previously [21]. In short, area-
specialised histopathologists identiﬁed and marked representative
areas on haematoxylin and eosin stained slides from formalin-ﬁxedparafﬁn-embedded tumour blocks, for tissue microarray construction.
Triplicate tissue cores (0.6 mm)were taken from themarked areas and
arrayed into separate recipient parafﬁn block using a manual tissue-
arrayer (Beecher Instruments, Silver Spring, MD, USA).
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Immunohistochemistry was performed as previously described
[22] with the following modiﬁcations. Microwave antigen retrieval
in pre-warmed 0.01 mol/L sodium citrate buffer (pH6) was con-
ducted for 10 min at 450 W. The primary antibody was diluted in
blocking solution, and incubated for 60 min at room temperature
(Thioredoxin interacting protein 1:3000 (MBL International Cor-
poration, Woburn, USA)). Blocking, secondary and ABC reagents
were supplied in kit form from Vector Labs (Universal PK-6200 or
Goat PK-6105, DAB SK-4100 (Vector Laboratories, Burlingame,
USA)) followed by 3,3’-diaminobenzidine (DAB) substrate (K3468Fig. 1. Photomicrographs of immunohistochemical Thioredoxin interacting protein ex
chemotherapy (left panels) or from primary surgery alone (right panels). Scale bars den(Dako, Glostrup, Denmark)). Primary antibody was omitted for
negative controls. Gastric tissue and historically used breast
composite blocks composed of six stage I breast carcinomas,
including grade I, II and III tumours were used for initial antibody
optimisations and positive controls. Antibody speciﬁcity was
assessed by Western blotting on gastric and breast cancer cell
lysates prior to commencing the study.
Assessment of expression
Assessment of expression of protein staining was conducted
independently by the specialist gastro-intestinal histopathologistpression patterns at 10 magniﬁcation in tumours after receiving neoadjuvant
ote 500 mm.
C.M. Woolston et al. / Redox Biology 1 (2013) 285–291288(IS) and the lead scientist (CW) blinded to the study end points.
Staining intensity was divided into four grades, none (0), weak
(1) moderate (2) and strong (3). Semiquantitative H scores were
calculated by multiplying the percentage of positive tumour cells
by the staining intensity, giving a range between 0 and 300. The
median H score for the three triplicate cores for each case was
then calculated and used in the ﬁnal assessments. To stratify the
cohort of patients into low- vs. high-expressing tumours, the
median of the two study populations was calculated and applied
(Neoadjuvant 77, Primary surgery 55).Fig. 2. Stem and Leaf plot demonstrating the differences in expression of Thior-
edoxin interacting protein (TxNIP) between primary surgery and those that
received neoadjuvant chemotherapy. A signiﬁcantly higher expression was noted
in the tumours that had received neoadjuvant chemotherapy compared to the
primary surgery cases (p¼0.007).Statistical analysis
SPSS version 15.0 statistical software package was used with
patients categorised into two groups, low and high (or negative
and positive), depending on whether their staining intensities fell
above or below the cut-off values. The Mann Whitney U test was
used to examine the Thioredoxin interacting protein expression
levels between the primary and neoadjuvant groups. The associa-
tion between protein expression and clinicopathological criteria
was assessed by univariate analysis using a Pearson χ2 test.
Survival analysis comparing protein expression levels with recur-
rence and overall survival were conducted using Kaplan-Meier
curves and the statistical signiﬁcance evaluated using the log rank
test. Cox proportional hazards model was used to test the
statistical independence and signiﬁcance of Thioredoxin interact-
ing protein versus available clinical parameters. Agreement
between the two independent observers was assessed using
intraclass correlations (0.850).Results
Thioredoxin interacting protein expression and pathological
associations
Fig. 1 demonstrates the diffuse, granular and sometimes het-
erogeneous cytoplasmic immunostaining for Thioredoxin interact-
ing protein in the tumour samples. In certain tumour cases, there
was also heterogeneous staining between the triplicate cores.
This had previously been observed in a selection of whole mount
sections for this marker but triplicate cores allow for this potential
heterogeneity to be represented. From Fig. 2 it can be seen that the
levels of Thioredoxin interacting protein expression signiﬁcantly
differed between the treatment approaches when comparing the
continuous data from each cohort using the Mann Whitney U test
(p¼0.007). There was a higher median of expression in the
tumours that had received neoadjuvant chemotherapy (77) than
the untreated primary surgery cases (55).Thioredoxin interacting protein associations in tumours receiving
primary surgery only
Table 2 shows the associations between Thioredoxin interact-
ing protein expression and pathological features in the cases that
had primary surgery. A signiﬁcant association was seen with high
Thioredoxin interacting protein expression and a lack of lymph
node involvement (N stage: Χ2 8.027, df¼1, p¼0.005), no peri-
neural invasion (Χ2 4.705, df¼1, p¼0.030) and well/moderate
tumour differentiation (Χ2 4.521, df¼1, p¼0.033).
In the primary surgery cases, no signiﬁcance was observed
between Thioredoxin interacting protein expression and disease
speciﬁc survival (p¼0.507) or risk of recurrence (p¼0.722).Thioredoxin interacting protein associations in tumours receiving
neoadjuvant chemotherapy prior to surgery
In the neoadjuvant cohort, Thioredoxin interacting protein only
showed association with lymph node involvement (N stage: Χ2
3.972, df¼1, p¼0.046), again high expression with a lack of
involvement but less signiﬁcant than in the primary surgery cases
(Table 2). No other signiﬁcant associations were found with
pathological features or with risk of recurrence (p¼0.169).
Fig. 3a shows that a high expression of Thioredoxin interacting
protein signiﬁcantly associates with improved disease speciﬁc
survival (p¼0.016) in those patients treated with neoadjuvant
chemotherapy. This was analysed against other parameters that
were found to be signiﬁcant under Cox univariate analysis (T stage,
N stage, vascular invasion), in a multivariate analysis approach,
and Thioredoxin interacting protein was found to be indepen-
dently associated with outcome (p¼0.002) (Table 3).
In this cohort, some received chemotherapy containing anthra-
cyclines (ECX/ECF) and some non-anthracycline based (CF/CX/
CarboF) treatment. Therefore we examined whether there was a
difference in the disease speciﬁc survival between these two
groups. A high expression of Thioredoxin interacting protein in
the anthracycline based treatment group still associated with
improved disease speciﬁc survival (p¼0.022) whereas in those
treated only with cisplatin and 5-FU, no association was seen
(p¼0.561) (Fig. 3b and c).Discussion
The results presented in the current study have demonstrated
that a high expression level of Thioredoxin interacting protein is an
independent determinant of good disease speciﬁc survival in
gastro-oesophageal patients that have received neoadjuvant che-
motherapy (p¼0.002). The predictive power of Thioredoxin inter-
acting protein appears more relevant to those neoadjuvant cases
that received treatment containing anthracyclines compared to
those in the CF treatment group (5-FU/cisplatin) but further
validation studies would be required to conﬁrm this. Woolston
et al., have previously shown the potentially predictive/prognostic
role of redox protein expression in tumours taken pre and post
neoadjuvant anthracycline based chemotherapy in locally advanced
primary breast cancer patients [17]. High Thioredoxin interacting
proteinwas an independent prognostic factor for an improved disease
free- and overall survival as well as a signiﬁcant increase in expression
between paired pre- and post-chemotherapy tumour samples.
P=0.016
High TxNIP
Low TxNIP
No at Risk
Low TxNIP
High TxNIP
32        16            6            3            2             1            0         
34         25           9             5            3 2 0
P=0.022 P=0.561
High TxNIP 
High TxNIP 
Low TxNIP 
Low TxNIP 
NNo at Risk o at Risk 
Low TxNIP 17 12 7 6 1 1 0 Low TxNIP 14 9 5 3 2 1 0
High TxNIP 21 20 16 13 4 0 0 High TxNIP 13 9 5 5 3 2 0
Fig. 3. Kaplan Meier survival curves. (A) High expression of Thioredoxin interacting protein (TxNIP) signiﬁcantly associated with a better disease speciﬁc survival (p¼0.016).
This was more apparent in the cases that had (B) anthracyclines included in their neoadjuvant treatment regime (p¼0.022) compared to those (C) without (p¼0.561).
Table 3
Cox proportional hazards analysis for disease speciﬁc survival in the neoadjuvant
treated patients and anthracycline based neoadjuvant treated patients. HR¼Hazard
ratio, CI¼Conﬁdence Interval, n¼po0.05.
Neoadjuvant treated patients
Thioredoxin interacting protein
Hazard ratio 95% Cl Signiﬁcance
Protein 0.4 0.2–0.7 0.002n
T stage 3.0 1.1–7.8 0.0.28n
N stage 3.0 1.3–6.7 0.009n
Vascular invasion 2.5 1.3–5.0 0.009n
Anthracycline based patients
Thioredoxin interacting protein
Hazard Ratio 95% Cl Signiﬁcance
Protein 0.3 0.1–0.7 0.008n
T stage 8.4 1.0–66.6 0.045n
N stage 2.2 0.7–6.9 0.159
Vascular invasion 2.5 0.7–8.1 0.136
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Thioredoxin interacting protein gene expression in 68 stage III
gastric cancer cases had a better recurrence free survival. In 85% of
gastric cancers that they went on to examine by immunohisto-
chemistry, 85% under expressed Thioredoxin interacting protein
compared to normal tissues with a tendency for this underexpression to occur in two poor prognostic groups: diffuse
histology and high stage [23].
It may well be that it is the differences in tumour site between
groups (i.e. 23 vs. 91% gastric) that is inﬂuencing the expression
differences seen between the neoadjuvant and primary surgery
groups; however, 5-FU could also be contributing to the expres-
sion differences. 5-FU upregulated Thioredoxin interacting protein
levels in a gene expression study [24] and is known to trigger
reactive oxygen species generation through as yet undetermined
mechanisms [25]. 5-FU also decreased Focal adhesion kinase
protein expression and up-regulated Thioredoxin interacting pro-
tein expression in 293 kidney cells [26]. The higher overall
expression of Thioredoxin interacting protein seen in tumours
examined after neoadjuvant therapy compared to primary surgery
(p¼0.007) may be indicative of redox pathways being activated in
response to therapy but further work is required in this area,
potentially by examining the expression of TxNIP in normal tissue
at different sites from which the tumours arise.
The effects of Thioredoxin interacting protein could be via
thioredoxin inhibition, allowing the reactive oxygen species gen-
erated by the cytotoxic agents to exert their damaging effects.
An increased level of reactive oxygen species has been observed in
ﬁbroblasts with increased levels of Thioredoxin interacting protein
[27] and preventing thioredoxin interacting with PAG or ASK-1 can
sensitise cells to oxidative stress [28]. However, in contrast, gene
silencing of Thioredoxin interacting protein in melanoma cells
reduced reactive oxygen species production [29] suggesting a
potential tumour speciﬁc effect. In gastric cancer, primary tumours
expressing high levels of thioredoxin have been shown to have a
C.M. Woolston et al. / Redox Biology 1 (2013) 285–291290higher proliferative rate and lower rate of spontaneous cell death
[30] and knockout of Thioredoxin interacting protein in a mouse
model induced Helicobacter pylori related gastric cancer [31].
Forced expression of Thioredoxin interacting protein in stomach
cancer and promyelocytic leukaemia cell lines inhibited their
proliferation [14]. Thioredoxin interacting protein is also regulated
by class II HDACs such as HDAC10. HDAC10 transcriptional down-
regulation of Thioredoxin interacting protein leads to altered
reactive oxygen species signalling in human gastric cancer cells
[32]. It appears, from such reports and from current results, that
indirect modulation of Thioredoxin interacting protein by agents
such as HDAC inhibitors may represent a promising therapeutic
approach.
In the primary surgery cohort of patients, although not sig-
niﬁcant for survival or recurrence, Thioredoxin interacting protein
did show signiﬁcant association with prognostic features such as
lymph node involvement (N stage p¼0.005), perineural invasion
(p¼0.030) and differentiation status of the tumour (p¼0.033).
M stage cases were not included in the analyses as only 6% of
primary surgery cases and 1% of neoadjuvant cases had distant
metastases reported. Thioredoxin interacting protein has been
demonstrated to suppress tumour growth and metastasis in
transplantation models [33] and suppress cell invasiveness and
tumour metastases of melanoma B16-F10 in in vivo models
possibly via its association with the β domain of von Hippel-
Lindau protein [34]. Loss of Thioredoxin interacting protein has
been demonstrated to be enough to induce malignancy, forming
hepatocellular carcinomas in mice [35]. In the case of differentia-
tion, Thioredoxin interacting protein is thought to play a role in
epithelial differentiation in the GI tract [36] with Thioredoxin
expression predominantly seen in undifferentiated gastric cancers
[37]. Such reports support current ﬁndings where high Thiore-
doxin interacting protein expression associates with better tumour
differentiation, lack of lymph node involvement and no perineural
invasion.
In summary, this study highlights the potential of Thioredoxin
interacting protein as a biomarker for response to reactive oxygen
species generating chemotherapy agents used in the neoadjuvant
setting in gastro-oesophageal adenocarcinoma. It also indicates its
role in tumour progression through its associations with patholo-
gical criteria.Acknowledgements
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